Current Perspectives on Coronary Chronic Total Occlusions The Canadian Multicenter Chronic Total Occlusions Registry by Fefer, Paul et al.
Journal of the American College of Cardiology Vol. 59, No. 11, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00Interventional Cardiology
Current Perspectives on
Coronary Chronic Total Occlusions
The Canadian Multicenter Chronic Total Occlusions Registry
Paul Fefer, MD,*† Merril L. Knudtson, MD,‡ Asim N. Cheema, MD, PHD,§
P. Diane Galbraith, BN, MSC,‡ Azriel B. Osherov, MD,* Sergey Yalonetsky, MD,*
Sharon Gannot, BS,† Michelle Samuel,* Max Weisbrod,* Daniel Bierstone,* John D. Sparkes, MSC,*
Graham A. Wright, PHD,* Bradley H. Strauss, MD, PHD*
Toronto, Ontario, and Calgary, Alberta, Canada; and Tel Aviv, Israel
Objectives The purpose of this study was to determine the prevalence, clinical characteristics, and management of coro-
nary chronic total occlusions (CTOs) in current practice.
Background There is little evidence in contemporary literature concerning the prevalence, clinical characteristics, and treat-
ment decisions regarding patients who have coronary CTOs identified during coronary angiography.
Methods Consecutive patients undergoing nonurgent coronary angiography with CTO were prospectively identified at
3 Canadian sites from April 2008 to July 2009. Patients with previous coronary artery bypass graft surgery or
presenting with acute ST-segment elevation myocardial infarction were excluded. Detailed baseline clinical, an-
giographic, electrocardiographic, and revascularization data were collected.
Results Chronic total occlusions were identified in 1,697 (18.4%) patients with significant coronary artery disease
(50% stenosis in 1 coronary artery) who were undergoing nonemergent angiography. Previous history of
myocardial infarction was documented in 40% of study patients, with electrocardiographic evidence of Q waves
corresponding to the CTO artery territory in only 26% of cases. Left ventricular function was normal in 50% of
patients with CTO. Half the CTOs were located in the right coronary artery. Almost half the patients with CTO
were treated medically, and 25% underwent coronary artery bypass graft surgery (CTO bypassed in 88%). Percu-
taneous coronary intervention was done in 30% of patients, although CTO lesions were attempted in only 10%
(with 70% success rate).
Conclusions Chronic total occlusions are common in contemporary catheterization laboratory practice. Prospective studies
are needed to ascertain the benefits of treatment strategies of these complex patients. (J Am Coll Cardiol
2012;59:991–7) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.12.007There is growing interest in percutaneous treatment of
chronic total occlusions (CTO) in coronary arteries due to
improvements in technique and observational evidence that
successful treatment of coronary CTO is associated with
significant changes in cardiac function and outcome (1–6).
However, there are scant data in the literature about the
prevalence, clinical characteristics, and treatment decisions
regarding patients identified with CTO during diagnostic
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accepted December 2, 2011.coronary angiography, particularly in the contemporary
catheterization laboratory setting. Two retrospective studies
from the 1990s suggested that the prevalence of CTO in
patients with coronary artery disease (CAD) on coronary
angiograms ranged from 33% to 52%, depending on the
definition of CAD (stenoses either 50% or 70%) (7,8).
These studies were limited by small numbers (7), and
because the retrospective design, information regarding
patient and lesion characteristics (including duration of
chronicity) was lacking. The purpose of our study was to
provide current data on the prevalence of CTO in current
catheterization laboratory practice, and to provide detailed
clinical and angiographic characteristics, and treatment
strategy of patients identified with de novo CTO in a large
prospective registry of consecutive patients undergoing cor-
onary angiography at 3 academic Canadian institutions.
c
1
m
t
o
(
t
e
r
i
a
u
d
e
s
a
(
o
a
r
s
(

t
3
(
i
S
F
F
M
l
Q
I
l
992 Fefer et al. JACC Vol. 59, No. 11, 2012
The Canadian CTO Registry March 13, 2012:991–7Methods
The Canadian Multicenter CTO
Registry is a prospective registry of
consecutive CTO patients identi-
fied at coronary angiography at 3
participating sites. Permission to
collect data was provided by each
participating hospital research eth-
ics board. Clinical data regarding
sociodemographic characteristics,
clinical and comorbid conditions,
and left ventricular (LV) function,
as well as details of the index oc-
clusion of interest and general cor-
onary anatomy were collected
from the APPROACH (Alberta
Provincial Project for Outcome
Assessment in Coronary Heart Disease) database, which
captures detailed clinical information on patients undergo-
ing coronary angiography (9). The CTO study population
was compared to a consecutive cohort of 7,680 patients who
were not post-CABG and underwent nonemergent coro-
nary angiography at 2 of the centers during the same period.
Specific angiographic characteristics were collected and
recorded on the Coronary Artery Reporting and Archiving
Tool (CARAT). At 1 of the sites, CTO identification and
characteristics were verified with a second review of all
angiograms that had been identified as containing CTO by
angiography operators.
The study population consisted of all patients undergoing
coronary angiography excluding patients with prior CABG
and those undergoing primary PCI due to ST-segment
elevation myocardial infarction (MI). The prevalence of
CTO in study patients was determined using 2 denomina-
tors: 1) all patients undergoing angiography; and 2) patients
with CAD (defined as a stenosis 50% in at least 1
oronary artery). Chronic total occlusion was defined as
00% luminal diameter stenosis without a discernable lu-
en and the absence of antegrade flow, known or assumed
o be 6 week’s duration, on the basis of prior angiography
r presence of a concordant acute coronary syndrome
ACS). An ACS was defined as hospitalization for anginal
ype chest pain or equivalent at rest or with minimal
xertion or of worsening quality and/or cardiac biomarker
ise and/or electrocardiographic changes consistent with
schemia. Lesions with bridging collaterals were identified
s CTO, and lesions defined as CTO but duration was
nknown were classified as “CTO duration unknown.”
Additional angiographic data included the number of
iseased coronary arteries (defined as stenosis 50%), the
xtent of CAD expressed as the Duke coronary score (a
core of 7 to 13 was considered high risk) (10), the location
nd angiographic severity of additional coronary lesions
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
CAD  coronary artery
disease
CCS  Canadian
Cardiovascular Society
CTO  chronic total
occlusion
LV  left ventricular
LVEF  left ventricular
ejection fraction
MI  myocardial infarction
PCI  percutaneous
coronary interventiondefined as 50% diameter stenosis), lesion length of thecclusion, vessel tortuosity, calcification, and CTO location
t the site of a significant bifurcation.
Data on LV function were collected from echocardiog-
aphy, and when absent, from LV angiography or nuclear
tudies. The LV function was classified by ejection fraction
EF) as follows: grade 1, normal LV function (LVEF
55%); grade 2, mildly reduced LV function (LVEF 40%
o 55%); grade 3, moderately reduced LV function (LVEF
0% to 39%); and grade 4, severely reduced LV function
LVEF 30%).
All electrocardiograms were interpreted by a cardiologist
nvestigator (P.F., A.B.O., S.Y.) using the revised European
ociety of Cardiology/American College of Cardiology
oundation/American Heart Association/World Heart
ederation definitions for electrocardiographic definition of
I (11), which include the following criteria: any Q wave in
eads V2 to V3 0.02 s or QS complex in leads V2 and V3;
wave0.03 s and0.1 mV deep or QS complex in leads
, II, aVL, aVF, or V4 to V6 in any 2 leads of a contiguous
ead grouping (I, aVL,V6; V4 to V6; II, III, and aVF); and
R wave 0.04 s in V1to V2 and R/S 1 with a concordant
positive T wave in the absence of a conduction defect.
Information regarding subsequent revascularization pro-
cedures was abstracted from the APPROACH study where
possible or by review of the PCI and CABG reports.
Statistical analysis. Statistical analyses were performed in
SAS version 9 (SAS Institute, Cary, North Carolina).
Baseline frequency data were assessed using Fisher’s exact
test; continuous data were assessed using the general linear
model with the least-squares mean option. A similar anal-
ysis was performed for the comparisons of the 3 follow-up
treatment groups, where probability of 0.05 or 0.01 was
maintained for each variable by using p values  0.0169 or
0.0033, respectively, for each of the 3 pairs of compari-
sons. A p value 0.05 was considered statistically
significant.
Results
During the study period (April 1, 2008, to July 31, 2009), a
total of 14,439 patients underwent coronary angiography at
the 3 participating centers. At least 1 coronary CTO was
present in 2,630 patients, for an overall prevalence of CTO
of 18.2%. In the excluded patient groups, the prevalence of
CTO in 1,469 post-CABG patients was 54% (including
multiple CTOs in 58% of these patients) and 10% noncul-
prit CTOs in 1,453 patients who underwent primary PCI
for acute ST-segment elevation MI.
The overall prevalence of CTO in the study population
using definition 1 (all patients) was 14.7%, and using
definition 2 (patients with CAD), it was 18.4%. In approx-
imately half of the patients, the CTO was of unknown
duration. The mean age of CTO patients was 66  11
years, and 81% were male (Table 1). Only 40% of the
patients had a history of prior MI, and 12% had a history of
heart failure. Nearly half of the CTO patients presented
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March 13, 2012:991–7 The Canadian CTO Registrywith an ACS, and only 13% reported no or only mild
symptoms (Canadian Cardiovascular Society [CCS] class
0/1). Left ventricular function was normal (grade 1) in
50% of patients, and only 17% had significantly reduced
LV function (grade 3 to 4). Differences between patients
with CTO and the general catheterization laboratory pa-
tients undergoing nonurgent coronary angiography are
shown in Table 1. Notably, they tended to be older and
icker, as shown by greater prevalence of all risk factors.
lthough the absolute differences are small, they also were
ore likely to have heart failure and concomitant peripheral
ascular and cerebrovascular disease, but were less likely to
resent with an ACS.
The distribution of solitary CTOs showed that 47% were
n the right coronary artery (RCA), whereas only 20% had
solitary CTO in the left anterior descending artery, and
6% in the left circumflex branch. Chronic occlusions in1
oronary artery were observed in 17%. The CTO location
Baseline Characteristics of Patients WithCoronary TOsTable 1 B seline Characteristics of Patients WithCoronary CTOs
CTO Group
(n  1,697)
Control Group
(n  7,680) p Value
Age, yrs 66 11 64 12 0.001
Male 1,365 (80) 5,391 (70) 0.001
Diabetes mellitus 573 (34) 1,975 (26) 0.001
Hypertension 1,254 (75) 5,115 (68) 0.001
Hyperlipidemia 1,374 (82) 5,826 (78) 0.001
Prior MI 654 (40) 1,704 (23) 0.001
Prior PCI 376 (22) 1,631 (22) 0.51
Smoker
Current 419 (33) 1,611 (24) 0.001
Previous 496 (39) 2,740 (41) 0.21
Heart failure 204 (12) 677 (9) 0.001
Peripheral vascular disease 129 (8) 310 (4) 0.001
Cerebrovascular disease 144 (9) 499 (7) 0.003
Dialysis 31 (2) 107 (1) 0.18
Malignancy 72 (4) 372 (5) 0.52
Indication type
Acute coronary syndrome 752 (46) 4,352 (67) 0.001
Stable coronary disease 881 (54) 2,163 (33) 0.001
CCS class
0 79 (5) 250 (3) 0.005
1 110 (7) 464 (6) 0.43
2 376 (22) 1,516 (20) 0.017
3 301 (18) 1,010 (13) 0.001
4 795 (47) 4,179 (54) 0.001
Medications
Aspirin 1,504 (90) 6,564 (87) 0.001
Beta-blockers 1,244 (74) 5,385 (71) 0.014
Insulin 125 (10) 560 (8) 0.048
ACEI/ARB 1,074 (65) 893 (12) 0.001
Long-acting nitrates 419 (25) 1,910 (25) 0.58
Lipid lowering/statins 1,329 (79) 5,445 (73) 0.001
Values are mean  SD or n (%).
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin-receptor blocker; CCS 
Canadian Cardiovascular Society; CTO chronic total occlusion; MImyocardial infarction; PCI
percutaneous coronary intervention.as in the proximal or middle portion of the coronaryarteries in 78% of cases (distribution of proximal or mid-
vessel occlusion per vessel: left anterior descending artery
84%; left circumflex branch 63%; RCA 80%). Multivessel
CAD (50% diameter stenosis) was present in 76% of
patients with CTOs, and 7% exhibited significant (50%)
stenosis of the left main trunk.
Angiographic characteristics of the subgroup of patients
whose angiograms were verified by a second review were
available for 512 vessels with CTO. Baseline characteristics
of this group were similar to those of the entire study group.
Occlusion duration was uncertain in 278 (54%) patients. A
reference angiogram performed 6 weeks before the index
angiogram was available for 12 patients (2%). No ACS 6
eeks was listed for 275 patients (54%), whereas a concor-
ant ACS 6 weeks was recorded for 125 patients (24%).
ridging collaterals were present in 122 (24%) patients.
Electrocardiograms were analyzed from 2 of the partici-
ating centers and were available for 1,287 (93%) patients.
eft and right bundle branch block were found in 6% and
% of patients, respectively. Atrial fibrillation was present in
%. Significant Q waves corresponding to the CTO terri-
ory were found for 32% of the RCA, 13% for the left
nterior descending artery, and 26% for the left circumflex
ranch.
Most CTOs (64%) were managed medically, defined as
bsence of revascularization (Fig. 1). In 26% of patients,
ABG was performed, with the CTO artery grafted in 88%
f these patients. Whereas PCI to either CTO or non-
TO arteries was undertaken in 515 (30%) patients, an
ttempt to treat the CTO artery was made in only 162
atients (10% of CTO patients), with an overall success rate
f 70%.
Characteristics of patients according to CTO manage-
ent strategy chosen are shown in Table 2. Compared with
atients referred for medical therapy, patients referred for
Figure 1 Management of CTO Registry Patients
Flow chart of chronic total occlusion (CTO) registry patients showing manage-
ment up to 12 months after index angiography. PCI  percutaneous coronary
intervention.
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The Canadian CTO Registry March 13, 2012:991–7CABG were less likely to have renal insufficiency, prior MI,
or coronary intervention, and were more likely to have left
main trunk involvement. Compared with patients referred
for CTO PCI, patients referred for CABG were more likely
to have diabetes mellitus, triple-vessel disease, and left main
trunk involvement. Compared with patients referred for
medical therapy, patients referred for CTO PCI were
younger and less likely to have diabetes, renal insufficiency,
prior MI, and complex coronary anatomy (triple-vessel
disease and/or high-risk coronary index). They were less
likely to have left main trunk involvement compared with
patients treated by CABG. Patients treated medically
tended to be slightly older than patients in the other 2
groups and had higher prevalence of high-risk findings such
as renal insufficiency, prior MI, and prior PCI. No signifi-
cant differences were noted in laboratory data such as
hemoglobin level and estimated glomerular filtration rate.
Significant differences in management were noted among
Patient Characteristics by CTO Treatment AllocationTable 2 Patient Characteristics by CTO Treatment Allocation
No Intervention (A)
(n  1,100)
CABG (B)
(n  435)
Clinical variables
Age, yrs 67 0.3 66 0.6
Male 867 (80) 364 (84)
Diabetes mellitus 375 (34) 162 (37)
Hypertension 825 (76) 310 (71)
Renal insufficiency 136 (12) 34 (8)
Hyperlipidemia 893 (82) 345 (79)
Prior myocardial infarction 482 (44) 126 (29)
Prior coronary intervention 287 (26) 55 (13)
Heart failure 151 (14) 43 (10)
Peripheral vascular disease 95 (9) 27 (6)
Cerebrovascular disease 107 (10) 32 (7)
Malignancy 55 (5) 16 (4)
Current/former smoker 609 (56) 261 (60)
Left ventricular grade
1–2, LVEF 30% 633 (81) 273 (85)
3–4, LVEF 30% 140 (19) 47 (15)
CCS angina class
0 59 (5) 31 (7)
1 69 (6) 30 (7)
2 232 (21) 101 (24)
3 184 (18) 82 (20)
4 553 (50) 176 (42)
Coronary anatomy
Left main disease 54 (5) 95 (22)
3-vessel CAD 579 (53) 230 (53)
CTO artery
Left anterior descending 207 (19) 83 (19)
Left circumflex 174 (16) 52 (12)
Right coronary 545 (50) 196 (45)
1 CTO 164 (15) 104 (24)
High-risk coronary index 632 (59) 255 (61)
Values are mean  SD or n (%). *Statistically significant (p  0.05 overall or p  0.0170 for ind
reatments).
CABG  coronary artery bypass graft surgery; CAD  coronary artery disease; LVEF  left ventthe 3 participating centers (Fig. 2), especially with regard toPCI to the CTO (16% of CTO patients in center 2, 9% of
CTO patients in center 1, and 1% of CTO patients in center 3;
p 0.001), whereas no differences among centers were noted in
the referral rate for CABG (25% of CTO patients in center 1,
28% in center 2, and 22% in center 3; p  NS).
Discussion
The Canadian Multicenter CTO Registry was established to
determine the prevalence, clinical characteristics, and clinical
management of CTO in patients undergoing coronary angiog-
raphy in a contemporary catheterization laboratory setting.
The main findings of the study are that the overall prevalence
of CTO in patients with CAD referred for nonemergent
coronary angiography is 18.4%, that the majority of CTO
patients had absence of Q waves with well-preserved myocar-
dial function, and that despite 87% of CTO patients with
CCS class 2 symptoms, CTO revascularization was only
PCI (C)
(n  162)
p Values
Overall B vs. A C vs. A C vs. B
63 0.8 * — * —
122 (75) — — — —
33 (20) † — † †
106 (65) — — — —
6 (4) * * † —
123 (76) — — — —
41 (25) † † † —
30 (19) † † — —
10 (6) † — — —
7 (5) — — — —
17 (10) — — — —
1 (1) — — — —
79 (49) — — — —
92 (90) — — — —
10 (10) — — — —
8 (5) — — — —
10 (7) — — — —
38 (25) — — — —
33 (22) — — — —
61 (41) — — — —
6 (4) † † — †
51 (31) † — † †
47 (29) — — — —
36 (22) — — — —
55 (34) — — — —
24 (15) — — — —
52 (35) † — † †
pairs of treatments). †Highly significant (p  0.01 overall or p  0.0033 for individual pairs of
jection fraction; other abbreviations as in Table 1.ividualattempted in 36% of the CTO patients.
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March 13, 2012:991–7 The Canadian CTO RegistryThe true prevalence of CTO in the general population is
unknown as a certain proportion of patients with CTO are
asymptomatic or minimally symptomatic. Previous studies
assessing prevalence have differed with regard to the refer-
ence population. Kahn et al. (7) found a CTO prevalence of
35% among 333 consecutive patients undergoing diagnostic
catheterization at a community hospital over 1 year and
were found to have at least 1 coronary stenosis 50%.
Christofferson et al. (8), in a registry of 8,004 consecutive
patients at a single center undergoing diagnostic cathe-
terization between 1990 and 2000, reported a 52%
prevalence of CTO among patients with at least 1
coronary stenosis 70%. Only limited information about
the clinical presentation was available in these studies
because of the retrospective design, and thus some of
these cases could have been acute or subacute occlusions.
In contrast, the present study prospectively collected data
in a large cohort of patients, and CTO was classified only
after systematic review of both clinical and angiographic
information.
Clinical characteristics. This is the first study to report on
the symptom status and clinical presentation of unselected
consecutive patients diagnosed with a CTO on coronary
angiography. Almost half of our patients underwent coro-
nary angiography because of ACS. Among patients with
stable coronary disease, approximately 74% were symptom-
atic (CCS 2). However, the symptoms cannot be defi-
nitely attributed to the CTO in multivessel disease cases.
Only 5% of patients with a CTO were asymptomatic in this
study. Previous studies have suggested that the potential
benefits of CTO revascularization are related to the pres-
ence of myocardial viability (12).
Several clinical and angiographic characteristics in a
significant number of study patients highlight the major
potential for reducing ischemia by a CTO intervention.
Notably, only 40% of patients undergoing angiography had
Figure 2 Management of CTO
Registry Patients by Treating Center
Management decisions regarding registry patients with chronic total occlusion
(CTO) according to treating center. Yellow bars indicate percutaneous coronary
intervention (PCI) CTO; dark purple bars indicate coronary artery bypass graft
surgery (CABG); and light purple bars indicate none. *p  0.001; **p  NS;
°p  0.001.known previous MI, and less than one-third had electro-cardiographic evidence of previous MI. Data on LV func-
tion showed that 50% of the patients with CTO had
normal LV function, and only a small minority of patients
had heart failure. Of interest, previous studies of CTO
patients specifically referred for PCI have reported previous
MI in 42% to 68% (4,12–16). The discrepancy between the
revascularization rates of CTO either by surgery or by PCI
(approximately 32% in our study) and normal or near
normal LV function suggests that a substantial proportion
of CTO patients with indirect evidence of myocardial
viability are not undergoing some form of revascularization.
To clarify this issue, future studies should include objective
assessment of viability in the CTO territory.
Angiographic characteristics. Few studies have prospec-
tively assessed angiographic characteristics of CTO. The
CTO was located in the RCA in 50% of de novo cases;
that finding is consistent with angiographic findings from
the National Heart, Lung, and Blood Dynamic Registry
(17). In addition, we performed a detailed angiographic
assessment of angiographic CTO characteristics at 1 of the
participating centers (Sunnybrook Medical Centre) in a
subgroup of 512 CTO. Despite using contemporary criteria
for definition of CTO, a CTO duration could not be
established in 54% of cases. Similar findings were reported
recently in a registry of 202 consecutive patients with CTO,
in which duration of CTO was indeterminate in 39% of
patients. Interestingly, indeterminate duration of CTO in
this study was a predictor of PCI procedural failure and
major adverse cardiac events (18). Other characteristics
helped in estimating the CTO chronicity, including lack of
an ACS within the previous 6 weeks in 54% and bridge
collaterals in 24%. A previous study (7) noted unfavorable
characteristics for PCI in 18% of all patients and in 29% of
patients with multivessel CAD. These characteristics may
explain, in part, why PCI to CTO is undertaken relatively
infrequently.
Patient management. Several studies have reported on
successful PCI of CTO in selected patients, but practice
trends with regard to management and referral pattern for
an all-comers population are poorly understood. In this
study, 64% of the CTOs were managed medically, whereas
CABG surgery was performed in 26% of patients. In
patients undergoing CABG, the CTO vessel was grafted in
88% of patients. Although 30% of patients overall had a
PCI procedure, only 162 patients (10% of CTO patients)
had a PCI attempt to the CTO. In all, 511 (30%) patients
had successful revascularization of their CTO by either
surgery or PCI. Previous large PCI registries have found
that CTO represent 12% to 15.6% of the overall PCI
patient population (17,19).
An analysis from the National Cardiovascular Data Reg-
istry attempted to assess the PCI attempt rate among
patients diagnosed with a CTO on diagnostic angiography.
The annual rate ranged from 11.7% of CTO in 2005 to
13.6% of CTO in 2004 (19). In our study, there was wide
996 Fefer et al. JACC Vol. 59, No. 11, 2012
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tion of overall CTO cases that were treated by PCI, ranging
from 1% to 16%. There are several possible reasons for this
disparity, including performance of angiography by cardiol-
ogists with differing views of the perceived benefits of CTO
interventions or the expectations of successful PCI revascu-
larization within individual institutions. Disparity in the
rates of CTO PCI attempts have been reported before and
have been linked to operator PCI volume (20). Previous
studies also report that only 11% to 15% undergoing PCI
for CTO were asymptomatic (4,12). Indeed, in our study,
88% of CTO patients treated with angioplasty were symp-
tomatic (i.e., CCS class 2 to 4).
The success rate (70%) observed in our study is consistent
with that of many previous registries (5), although more
recent studies from CTO specialized centers have reported
success rates 80% (21,22).
Not unexpectedly, patients referred for CABG were more
likely to be older, with more comorbidities and more
extensive CAD, including left main involvement, than
patients referred for PCI. However, there were no differ-
ences in the location of the CTO artery, the presence of 1
CTO, symptom status, and LV function between CABG
and PCI patients. In general, patients referred for medical
therapy had more high-risk characteristics such as higher
prevalence of renal insufficiency and prior MI and PCI,
which may explain, in part, why revascularization proce-
dures were not undertaken in these patients.
Study limitations. The major limitation of this observa-
tional study is the lack of randomization to different
treatment strategies. The inclusion of only 3 institutions
may be related to the large variability noted in treatment
allocation between centers. A larger sample may have
reduced this variability. Another weakness is the lack of
accurate documentation of viability or ischemia in the
territory supplied by the CTO, or whether this information
was related to the decision to intervene in the CTO or not.
Nevertheless, our study does identify current prevalence,
clinical characteristics, and treatment allocation in the real
world in 3 large-volume centers in Canada.
Conclusions
The present study provides information for CTO preva-
lence in a contemporary catheterization laboratory practice
with detailed characterization of clinical and angiographic
parameters and management trends. The results show
that approximately 1 in 5 non-CABG patients with
significant CAD were found to have a CTO. In addition,
most patients are symptomatic and have preserved LV
systolic function without a clinical history of a prior MI
or the presence of Q waves on electrocardiography.
Despite major advances in surgical and percutaneous
revascularization over the last decade, many patients with
a CTO were managed medically, with rates similar tothose reported by older registries (20). Randomized
controlled trials are needed to compare medical manage-
ment with revascularization of CTO.
Reprint requests and correspondence: Dr. Bradley H. Strauss,
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Bayview Avenue, Room D-406, Toronto, Ontario M4N 3M5,
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